Delta-Opioid Receptor Surface Trafficking for Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management using opioid drugs is limited by adverse effects such as addiction, tolerance, and inefficient analgesia due to the low bioavailability of delta-Opioid Receptors (DOR) on the neuronal surface, which are retained in intracellular pools and not readily accessible for drug binding.
Innovation Solution
Identifying and targeting enzymes like phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K) to reverse DOR retention mechanisms, facilitating the surface trafficking of DOR by using activators like 740YPDGFR and PTEN inhibitors to increase DOR bioavailability on the neuronal surface, allowing DOR agonists to be used at lower doses for analgesia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid drugs are used to manage pain, then analgesic effect is achieved, but adverse effects such as addiction and tolerance occur
Solution Approach 1:
The invention extracts and isolates the analgesic function from the addictive mu-opioid receptor pathway by targeting the delta-opioid receptor instead. DOR agonists provide pain relief without activating the reward pathway that causes addiction, effectively separating the therapeutic effect from the harmful side effects.
Solution Approach 2:
The invention changes the target parameter from MOR to DOR, and further optimizes by increasing DOR surface expression through PI3K activation and PTEN inhibition. This parameter change enables effective analgesia with lower doses and reduced adverse effects compared to traditional MOR agonists.
2Reliability
If DOR agonists are used at higher doses to achieve analgesia, then pain relief is improved, but adverse effects increase
Solution Approach 1:
The invention changes the bioavailability parameter of DOR by manipulating its surface expression through enzymatic regulation. By activating PI3K and inhibiting PTEN, the patent increases the number of DOR on the neuronal surface, allowing lower doses of agonists to achieve the same analgesic effect with fewer side effects.
3Reliability
If DOR surface expression is increased to improve analgesia, then drug effectiveness increases, but the complexity of the treatment approach increases
Solution Approach 1:
The invention introduces enzymatic mediators (PI3K activators and PTEN inhibitors) that naturally regulate DOR surface expression. These intermediaries provide a biological mechanism to enhance DOR availability without requiring complex delivery systems or surgical interventions, simplifying the overall treatment approach.
Data Source
AI summary
Described herein is a method to induce surface trafficking of the delta-Opioid Receptor (DOR) and its applications, including, leveraging the antinociceptive potential of DOR agonists to treaty neurologic disorders and to be analgesics without the adverse consequences normally associated with chronic treatment by MOR agonists by inducing surface trafficking of the delta-Opioid Receptor (DOR) and screening compounds to identify additional targets for stimulated DOR delivery.